What should you know about lung cancer Tagrisso?

Tagrisso, also called osimertinib, blocks signals made by certain altered EGFR proteins that can help cancer cells grow. It is taken by mouth according to the prescribed schedule. It is not suitable for every lung cancer: tumour results, stage, previous treatment, other health conditions, and possible medicine interactions all matter. Genomic tumour profiling may be used to look for changes that affect treatment choices. The oncologist will explain whether the result supports Tagrisso and what benefit is realistic for the individual.

Take Tagrisso exactly as prescribed and tell the team about every medicine, supplement, and herbal product. Do not double a missed dose unless the prescriber gives that instruction. Keep a record of new diarrhoea, rash, dry skin, mouth soreness, nail changes, cough, or breathlessness. Monitoring may include symptom checks, examination, blood tests, heart checks, or scans depending on your plan. Never stop the medicine suddenly without contacting the oncology team.

Contact the treatment team urgently for new or worsening breathlessness, chest pain, fainting, a fast or irregular heartbeat, severe diarrhoea, dehydration, eye pain or vision change, or a widespread blistering rash. Sudden weakness, difficulty speaking, or a seizure needs emergency help. Prompt reporting lets clinicians assess whether symptoms are related to treatment or another illness.

Which tumour result makes Tagrisso appropriate for me? How should I take it if I vomit or miss a dose? Which monitoring tests will I need? Which medicines or foods could interact with it?